Claims for Patent: 9,493,567

Summary for Patent: 9,493,567

Title:	Methods of treating inflammatory and autoimmune diseases with natalizumab
Abstract:	Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn\'s Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Inventor(s):	Lieberburg; Ivan (Berkeley, CA)
Assignee:	Biogen Inc. (Cambridge, MA)
Application Number:	12/757,305
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,493,567
Patent Claims:	1. A method of treating a patient with an inflammatory or autoimmune disease comprising the steps of: (a) testing the patient for the presence of anti-JC virus (JCV) antibodies by a method consisting of measuring the presence of anti-JCV antibodies in the serum or plasma of a blood sample from the patient; (b) initiating treatment of the patient tested in step (a) by administering natalizumab to the patient in the event the sample is negative for anti-JCV antibodies; (c) testing the patient treated in step (b) for indicators of progressive multifocal leukoencephalopathy (PML) by detecting the presence of JCV in the patient's cerebrospinal fluid, or detecting clinical and/or radiologic symptoms of PML in said patient, and (d) further administering natalizumab to the patient in the absence of indicators of PML or discontinuing natalizumab treatment in the presence of indicators of PML. 2. The method of claim 1, wherein the indicators of PML comprise new or worsening neurological symptoms. 3. The method of claim 2, wherein the neurological symptoms comprise one or more of central blindness, mental confusion, personality change, and dyskinesia. 4. The method of claim 1, wherein the radiologic symptoms comprise lesions detected by a Gd-enhanced magnetic resonance imaging scan. 5. The method of claim 1, wherein the disease is multiple sclerosis. 6. The method of claim 5, wherein the multiple sclerosis is selected from relapsing remitting, secondary progressive, primary progressive, and chronic progressive multiple sclerosis. 7. The method of claim 6, wherein the multiple sclerosis (MS) is relapsing remitting MS. 8. The method of claim 6, wherein the multiple sclerosis is secondary progressive MS. 9. The method of claim 6, wherein the multiple sclerosis is primary progressive MS. 10. The method of claim 6, wherein the multiple sclerosis is chronic progressive multiple sclerosis. 11. The method of claim 1, wherein the disease is inflammatory bowel disease. 12. The method of claim 11, wherein the inflammatory bowel disease is Crohn's disease.

Details for Patent 9,493,567

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2026-02-28